Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 2/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGAV | P06756 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | NPR3 | P17342 | 1/20 | 0.44 |
| ▸ | PPIG | Q13427 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076211 | 1.00 | PPID (0.49) | PPIDITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL8207106 | 0.91 | TPSAB1 (0.48) | PPIDITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL14856593 | 0.89 | TPSAB1 (0.49) | PPIDMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14856517 | 0.88 | NPR3 (0.44) | PPIDMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13153852 | 0.88 | NPR3 (0.44) | PPIDMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14856518 | 0.88 | NPR3 (0.44) | PPIDMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL16472972 | 0.88 | NPR3 (0.44) | PPIDMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL18074199 | 0.86 | NPR3 (0.43) | PPIDMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL20971944 | 0.86 | NPR3 (0.43) | PPIDMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL16458225 | 0.86 | NPR3 (0.43) | PPIDMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| EP-3530290-A1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| EP-3530290-A1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-1964577-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| EP-1877098-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2013-04-24 | — | — | EP | disclosed |
| US-20090118311-A1 | DHFR Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-07 | — | — | US | disclosed |
| EP-2013189-A1 | DHFR ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| EP-1964577-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964577-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964578-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964578-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1877098-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007132146-A1 | DHFR ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-22 | — | — | WO | disclosed |
| WO-2006117567-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117567-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | PPID 3036/4885ITGB1 2192/4885ITGA5 2843/4885 |
| US-20090118311-A1 | DHFR Enzyme Inhibitors | DHFR, MTHFD1, ALDH7A1 | PPID 2510/4885ITGB1 4197/4885ITGA5 4052/4885 |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | PPID 3036/4885ITGB1 2192/4885ITGA5 2843/4885 |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | PPID 3036/4885ITGB1 2192/4885ITGA5 2843/4885 |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | PPID 3036/4885ITGB1 2192/4885ITGA5 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.